Results
Using a patient cohort (n=315), it was found that CYP2D6 IM and PM
patients had 1.9-fold (95%CI: 1.4-2.7) and 9.6-fold (5.9-16) higher
exposure of atomoxetine compared with CYP2D6 NMs. CYP2C19*2carriers had 1.5-fold (1.1-2.2) higher atomoxetine exposure than
non-carriers regardless of CYP2D6 genotype.